New combo therapy shows promise for hard-to-treat melanoma

NCT ID NCT04796194

First seen Nov 20, 2025 · Last updated Apr 30, 2026 · Updated 21 times

Summary

This study tested a new drug combination for people with advanced melanoma that no longer responds to standard immunotherapy. The treatment involves injecting a drug called LTX-315 directly into tumors along with an intravenous immunotherapy drug, pembrolizumab. The goal was to see if this approach could shrink tumors or slow the disease in 23 participants who had exhausted other options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Akershus University Hospital

    Lørenskog, Norway

  • Centre Hospitalier Regional Universitaire De Lille

    Lille, France

  • Clínica Universidad de Navarra

    Pamplona, Spain

  • Gustave Roussy Cancer Campus

    Paris, France

  • Hospital Lyon Sud

    Pierre-Bénite, France

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Levine Cancer Institute - Atrium Health

    Charlotte, North Carolina, 28204, United States

  • MD Anderson Cancer Centre

    Houston, Texas, 77030, United States

  • Oslo University Hospital--Radiumhospitalet

    Oslo, Norway

  • University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.